Patients with higher FLI-1 expression in ovarian cancer, astrocytoma, non-small cell lung cancer, plasmablastic lymphoma and nasopharyngeal carcinoma have poor overall survival (OS) [74–76, 79, 80]. This evidence concerns the gene FLI1 and ovarian cancer.